TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06758557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv d1
Study: NCT06295926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
Study: NCT06637540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RescueDoppler
Description: Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RescueDoppler
Description: Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
Study: NCT04866472

Intervention type: DEVICE
Group type: OTHER
Intervention: video-laryngoscope and GlideRite Rigid Stylet
Description: Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-laryngoscope and TCI Articulating Introducer Device
Description: In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
Study: NCT05187481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Huatan dispensing granule
Description: once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granule
Description: once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
Study: NCT06758557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv d1
Study: NCT06764992

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to complete a questionnaire on demographics, risk beliefs and perception and prostate cancer screening behaviors, intentions and awareness of informed decision making.

Intervention type: OTHER
Intervention: Saliva Sample
Description: Participants will be asked to provide a saliva sample for genetic risk testing to generate a SNP risk profile using a saliva sample collection kit with collection, storage and mailing instructions. We will assess the proportion of consented men who will provide a saliva sample.
Study: NCT06769477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Group
Description: individuals will receive diabetes education with motivational interviewing technique based on health belief model
Study: NCT05468320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: Lyophilized powder for solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Solution for injection or Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD20 antibody
Description: Solution for injection
Study: NCT06777433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD101 (18F-FPIA)
Description: A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
Study: NCT06768190

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: WhatsApp as usual
Description: Pregnant women and their partners are instructed to use WhatsApp as normal for six weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp-based psycho-socio-educational intervention (WeLove)
Description: The intervention comprises six sessions, including psychoeducation, communication training, sleep hygiene, stimulus control, cognitive restructuring, and behavioural activation. Each session has two short videos, quizzes, forums, and homework. The content is presented through a virtual midwife using storytelling of real-life scenarios, animation, and case vignettes about psychological and sleep problems during pregnancy. A virtual midwife acts as an educator to explain the prevalence, causes, and factors of psychological and sleep problems. Every session will concentrate on certain courses and offer specialised advice to expectant mothers and their partners. Using the security links on the WhatsApp platform, each session takes 15 to 20 minutes to finish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp-based psycho-socio-educational intervention (WeLove)
Description: The intervention comprises six sessions, including psychoeducation, communication training, sleep hygiene, stimulus control, cognitive restructuring, and behavioural activation. Each session has two short videos, quizzes, forums, and homework. The content is presented through a virtual midwife using storytelling of real-life scenarios, animation, and case vignettes about psychological and sleep problems during pregnancy. A virtual midwife acts as an educator to explain the prevalence, causes, and factors of psychological and sleep problems. Every session will concentrate on certain courses and offer specialised advice to expectant mothers and their partners. Using the security links on the WhatsApp platform, each session takes 15 to 20 minutes to finish.
Study: NCT06774170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured follow-up intervention
Description: The intervention has been created in light of the studies including type 1 and type 2 diabetes patients and experiences of the project team with patients after PD. Theoretical background of the intervention is based on the interventions developed for glucose management in type 1 and type 2 diabetes patients and the effect of the intervention will be evaluated by using the plan-do-check-act model.
Study: NCT06779292

Intervention type: DIAGNOSTIC_TEST
Intervention: Large Language Model Diagnosis
Description: Using the large language model for diagnosing emergency neurology conditions.
Study: NCT06780111

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg via IV infusion
Study: NCT05464394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injection [Cyklokapron]
Description: A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: 100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
Study: NCT05636735

Intervention type: OTHER
Intervention: data collection
Description: evaluation of self -confidence
Study: NCT06367114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ssCART-19
Description: Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied.
Study: NCT05004012

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetically Controlled Capsule Endoscopy
Description: This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetically Controlled Capsule Endoscopy
Description: This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetically Controlled Capsule Endoscopy
Description: This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
Study: NCT06367114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT05676645

Intervention type: DRUG
Intervention: Artemether-lumefantrine
Description: National policy recommendation for treatment of uncomplicated malaria in Uganda
Study: NCT06780111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-DXd
Description: 12 mg/kg via IV infusion
Study: NCT05789342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681
Description: GP681, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681
Description: GP681, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681
Description: GP681, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681
Description: GP681, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir, capsule, oral
Study: NCT01604200

Intervention type: BEHAVIORAL
Intervention: focus group
Description: key informant review
Study: NCT06780111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-DXd
Description: 12 mg/kg via IV infusion
Study: NCT05004012

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetically Controlled Capsule Endoscopy
Description: This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
Study: NCT05845190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises
Description: aerobic exercises in form of walking on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercises
Description: 60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
Study: NCT05099276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Pill
Description: 1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
Study: NCT04831944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.
Study: NCT06780111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m\^2 via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin
Description: 200 mg/m\^2 via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: 200 mg/m\^2 via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous IV infusion for 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous IV infusion for 48 hours
Study: NCT05176678

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1 gram of a protein hydrolysate
Description: After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1 gram of a protein hydrolysate
Description: After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 grams of a protein hydrolysate
Description: After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 grams of a protein hydrolysate
Description: After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4 grams of a protein hydrolysate
Description: After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 8 grams of a protein hydrolysate
Description: After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
Study: NCT06398392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PBR111
Description: \[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBR111 injection
Description: \[18F\]PBR111 will be administered once, intravenously in the antecubital fossa at a dose of 200 MBq

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Upon administration of the radiotracer, a 120-minute PET/CT scan will be initiated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBR111 dosimetry
Description: to establish the exposure of the organs/tissues to a standard radioactive dose (200 MBq) of \[18F\]PBR111
Study: NCT06780111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous IV infusion for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m\^2 via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m\^2 via IV infusion
Study: NCT06774508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFE+cog
Description: Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Simultaneous cognitive exercises are added to static and dynamic balance exercises. Relative exercise intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIFE
Description: Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Relative exercises intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
Study: NCT04055389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Description: Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No study drug
Study: NCT04844346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol mini drinks
Description: Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mini drinks
Description: Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 vaccine
Description: First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Study: NCT06777927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
Study: NCT05178134

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etvax
Description: Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etvax
Description: Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
Study: NCT04943588

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV RNA (PCR)
Description: We will test HCV positive patients after treatment to observe if they achieve SVR

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV RNA (PCR)
Description: We will test HCV positive patients after treatment to observe if they achieve SVR

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV Antibody test (Point of care)
Description: HCV antibody test used to establish if patients have had or are actively infected with HCV

Intervention type: DIAGNOSTIC_TEST
Intervention: AST/ALT and platelets measurement
Description: AST/ALT and platelets to determine APRI score
Study: NCT05641454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ElevATP supplement
Description: ElevATP supplement containing apple and ancient peat extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study: NCT04844346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Study: NCT05965934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Sodium Removal Infusate 2.0
Description: Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
Study: NCT06777927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The subjects would be doing treadmill training within moderate intensity target heart rate.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The subjects would not be given any intervention and would be used as controls.
Study: NCT05188612

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)

Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)